Abstract:Terminal differentiation of B cells depends on two interconnected survival pathways, elicited by the B-cell receptor (BCR) and the BAFF receptor (BAFF-R), respectively. Loss of either signaling pathway arrests B-cell development. Although BCR-dependent survival depends mainly on the activation of the v-AKT murine thymoma viral oncogene homolog 1 (AKT)/PI3-kinase network, BAFF/BAFF-R-mediated survival engages non-canonical NF-κB signaling as well as MAPK/extracellular-signal regulated kinase and AKT/PI3-kinase modules to allow proper B-cell development. Plasma cell survival, however, is independent of BAFF-R and regulated by APRIL that signals NF-κB activation via alternative receptors, that is, transmembrane activator and CAML interactor (TACI) or B-cell maturation (BCMA). All these complex signaling events are believed to secure survival by increased expression of anti-apoptotic B-cell lymphoma 2 (Bcl2) family proteins in developing and mature B cells. Curiously, how lack of BAFF- or APRIL-mediated signaling triggers B-cell apoptosis remains largely unexplored. Here, we show that two pro-apoptotic members of the ‘Bcl2 homology domain 3-only’ subgroup of the Bcl2 family, Bcl2 interacting mediator of cell death (Bim) and Bcl2 modifying factor (Bmf), mediate apoptosis in the context of TACI-Ig overexpression that effectively neutralizes BAFF as well as APRIL. Surprisingly, although Bcl2 overexpression triggers B-cell hyperplasia exceeding the one observed in Bim−/−Bmf−/− mice, Bcl2 transgenic B cells remain susceptible to the effects of TACI-Ig expression in vivo, leading to ameliorated pathology in Vav-Bcl2 transgenic mice. Together, our findings shed new light on the molecular machinery restricting B-cell survival during development, normal homeostasis and under pathological conditions. Our data further suggest that Bcl2 antagonists might improve the potency of BAFF/APRIL-depletion strategies in B-cell-driven pathologies.

Insights into the role of Bcl6 in follicular Th cells using a new conditional mutant mouse model.

A Bcl6 Intronic Element Regulates T Follicular Helper Cell Differentiation

Genomic deletion of Bcl6 differentially affects conventional dendritic cell subsets and compromises Tfh/Tfr/Th17 cell responses

The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment

The transcriptional repressor Bcl6 controls the stability of regulatory T cells by intrinsic and extrinsic pathways.

Bcl6 is the nexus transcription factor of T follicular helper cell (TFH) differentiation via a set of repressor-of-repressor gene circuits

Bcl6 expression specifies the T follicular helper cell program in vivo.

Follicular Regulatory T Cells Repress Cytokine Production by Follicular Helper T Cells and Optimize IgG Responses in Mice

Bcl6-Independent In Vivo Development of Functional Type 1 Classical Dendritic Cells Supporting Tumor Rejection

Bcl6-Mediated Transcriptional Regulation of Follicular Helper T cells (TFH)

BCL6 Controls Contact-Dependent Help Delivery During Follicular T-B Cell Interactions

Bcl6 Promotes Follicular Helper T-Cell Differentiation and Pd-1 Expression in A Blimp1-Independent Manner in Mice

BCL6 deletion in CD4 T cells does not affect Th2 effector mediated immunity in the skin

Mutual Inhibition Between Prkd2 and Bcl6 Controls T Follicular Helper Cell Differentiation

An Inhibitory Role for the Transcription Factor Stat3 in Controlling IL-4 and Bcl6 Expression in Follicular Helper T Cells.

Thymic Selection Can Compensate for Mutations Affecting T Cell Activation and Generate a Normal T Cell Repertoire in Mutant Mice

Deficiency in T Follicular Regulatory Cells Promotes Autoimmunity

Combined loss of the BH3-only proteins Bim and Bmf restores B-cell development and function in TACI-Ig transgenic mice

The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation

Bcl11b: a novel regulator of T-lineage commitment